Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: August 30, 2024
Reporting Period: Single event date (August 30, 2024)
This filing serves as a Regulation FD disclosure regarding the pricing of an upsized public offering of common stock and warrants. The offering includes participation from management, directors, institutional investors, and certain existing investors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report announcing a capital raise event rather than a periodic financial statement (10-K or 10-Q).
Material Changes
- Capital Structure Change: The Company announced the pricing of an upsized public offering involving the sale of common stock and warrants.
- Investor Participation: The offering includes participation from management, directors, institutional investors, and existing investors.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) containing the full details of the offering pricing. No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this 8-K summary.
Unusual Items: The "upsized" nature of the offering and the participation of management and directors are notable features of this capital event.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific number of shares, warrant terms, and total capital raised.
- Verify the subscription details for management, directors, and existing investors to assess alignment of interests.
- Check the use of proceeds outlined in the accompanying press release to understand how the capital will be deployed.
- Confirm the trading status of the new securities on The Nasdaq Capital Market.